27 related articles for article (PubMed ID: 38518871)
1. Mechanism of Induction of P-gp Activity During MET Induced by DEX in Lung Cancer Cell Line.
Liu W; Zhang X; Sunakawa H; Perera LMB; Martha L; Mizoi K; Ogihara T
J Pharm Sci; 2024 Jun; 113(6):1674-1681. PubMed ID: 38432625
[TBL] [Abstract][Full Text] [Related]
2. The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel.
Li QQ; Cao XX; Xu JD; Chen Q; Wang WJ; Tang F; Chen ZQ; Liu XP; Xu ZD
Cell Mol Life Sci; 2009 Feb; 66(3):504-15. PubMed ID: 19099191
[TBL] [Abstract][Full Text] [Related]
3. mRNA-responsive two-in-one nanodrug for enhanced anti-tumor chemo-gene therapy.
Liu Y; Lin Y; Xiao H; Fu Z; Zhu X; Chen X; Li C; Ding C; Lu C
J Control Release; 2024 May; 369():765-774. PubMed ID: 38593976
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic priming modulates cellular ATP levels to overcome P-glycoprotein-mediated drug efflux in chemoresistant triple-negative breast cancer.
Rahman I; Liang B; Sajid A; Ambudkar SV; Huang HC
Photochem Photobiol; 2024 Jun; ():. PubMed ID: 38824410
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Oral Chemotherapeutic Reversal Agents for Treating Multidrug Resistance Cancer.
Yu KH; Wu IT; Yu CP; Wang WC; Chi CH; Tsai KC; Chou CH; Hung CC; Hung HY
Eur J Pharmacol; 2024 May; ():176682. PubMed ID: 38823759
[TBL] [Abstract][Full Text] [Related]
6. Cancer drug resistance: redox resetting renders a way.
Liu Y; Li Q; Zhou L; Xie N; Nice EC; Zhang H; Huang C; Lei Y
Oncotarget; 2016 Jul; 7(27):42740-42761. PubMed ID: 27057637
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Review on Current Treatments and Challenges Involved in the Treatment of Ovarian Cancer.
Saman S; Srivastava N; Yasir M; Chauhan I
Curr Cancer Drug Targets; 2024; 24(2):142-166. PubMed ID: 37642226
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies to overcome taxane resistance in cancer.
Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
[TBL] [Abstract][Full Text] [Related]
9. Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways.
Ganesan M; Kanimozhi G; Pradhapsingh B; Khan HA; Alhomida AS; Ekhzaimy A; Brindha GR; Prasad NR
Biomed Pharmacother; 2021 Jul; 139():111632. PubMed ID: 34243600
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of Paclitaxel/Atovaquone/Quercetin to regulate energy metabolism to reverse multidrug resistance in ovarian cancer by PLGA-PEG nanoparticles.
Lu Q; Gao W; Chen Z; Liu Z; Wang J; Zeng L; Hu X; Zheng E; Zhang Q; Song H
Int J Pharm; 2024 Apr; 655():124028. PubMed ID: 38518871
[TBL] [Abstract][Full Text] [Related]
11. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.
Dong X; Mattingly CA; Tseng MT; Cho MJ; Liu Y; Adams VR; Mumper RJ
Cancer Res; 2009 May; 69(9):3918-26. PubMed ID: 19383919
[TBL] [Abstract][Full Text] [Related]
13. Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.
Zhao MD; Li JQ; Chen FY; Dong W; Wen LJ; Fei WD; Zhang X; Yang PL; Zhang XM; Zheng CH
Int J Nanomedicine; 2019; 14():9453-9467. PubMed ID: 31819443
[TBL] [Abstract][Full Text] [Related]
14. 3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function.
Jin L; Yingchun W; Zhujun S; Yinan W; Dongchen W; Hui Y; Xi Y; Wanzhou Z; Buluan Z; Jinhua W
Biomed Pharmacother; 2019 Aug; 116():108992. PubMed ID: 31129513
[TBL] [Abstract][Full Text] [Related]
15. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.
Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y
J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
